Dietary delivery of glycomacropeptide within the whey protein matrix is not effective in mitigating tissue ceramide deposition and obesity in mice fed a high-fat diet

• Published in: Journal of dairy science 2024-02, Vol.107 (2), p.669-682
• Main Authors: de Hart, Naomi M.M.P., Petrocelli, Jonathan J., Nicholson, Rebekah J., Yee, Elena M., van Onselen, Lisha, Lang, Marisa J., Bourrant, Paul-Emile, Ferrara, Patrick J., Bastian, Eric D., Ward, Loren S., Petersen, Brent L., Drummond, Micah J.
• Format: Article
• Language: English
• Subjects: adiposity; animal models; Animals; Caseins; Ceramides; dairy science; Diet, High-Fat; glucose; Glucose Intolerance - veterinary; high fat diet; inflammation; Inflammation - veterinary; Insulin Resistance; lipogenesis; liver; low fat diet; Male; males; Mice; Mice, Inbred C57BL; obesity; Obesity - veterinary; Peptide Fragments; peptides; Rodent Diseases; skeletal muscle; Sphingolipids; Weight Gain; whey protein; whey protein isolate; Whey Proteins; young adults
• ISSN: 0022-0302; 1525-3198
• DOI: 10.3168/jds.2023-23914

Obesity is often accompanied by heightened circulating and tissue inflammation along with an increase in sphingolipids (e.g., ceramides) in metabolically active and insulin-sensitive organs. Whey protein isolate (WPI) has been shown to decrease inflammation and increase insulin sensitivity when given during a high-fat diet (HFD) intervention in rodents. The whey protein bioactive peptide glycomacropeptide (GMP) has also been linked to having anti-inflammatory properties and regulating lipogenesis. Therefore, the purpose of the study was to determine the effect of dietary GMP within the whey protein matrix on tissue inflammation, adiposity, and tissue ceramide accumulation in an obesogenic rodent model. Young adult male mice (10 wk old) underwent a 10-wk 60% HFD intervention. Glycomacropeptide was absent in the control low-fat diet and HFD WPI (−GMP) groups. The HFD WPI (1×GMP) treatment contained a standard amount of GMP, and HFD WPI (2×GMP) had double the amount. We observed no differences in weight gain or reductions in adiposity when comparing the GMP groups to HFD WPI (−GMP). Similarly, insulin resistance and glucose intolerance were not offset with GMP, and skeletal muscle and liver tissue ceramide content was unaltered with the GMP intervention. In contrast, the additional amount of GMP (2×GMP) might adversely affect tissue obesity-related pathologies. Together, dietary GMP given in a whey protein matrix during an HFD intervention does not alter weight gain, insulin resistance, glucose intolerance, and sphingolipid accumulation in the liver and skeletal muscle.